Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy

Table 2 Dynamic evolution of serum anti-PLA2R antibody titer in CTX and CYA groups during the six-month immunosuppressive treatment period

Characteristics	CTX group (n = 23)	CYA group (n = 24)	P value
Anti-PLA2R titer (RU/mL), M (P₂₅, P₇₅)
One month	3.6 (1.6, 58.9)	30.1 (3.8, 130.7)	0.04
Three months	1.9 (1.5, 30.7)	3.9 (2.1, 43.1)	0.06
Six months	1.7 (1.3, 4.3)	2.9 (1.6, 36.4)	0.08
Seroconversion of Anti-PLA2R antibody, n (%)
One month	16 (69.6)	7 (29.2)	0.01
Three months	17 (73.9)	14 (58.3)	0.26
Six months	18 (78.3)	16 (66.7)	0.37

CTX cyclophosphamide, CYA cyclosporine A, PLA2R phospholipase A 2 receptor

ISSN: 1471-2369